May 9 2005  

 

Veenendaal, The Netherlands,- The Akademiska Hospital In Uppsala Sweden has treated the first clinical IMRT patient using the Oncentra MasterPlan suite of treatment planning from Nucletron. This is the first patient in the world to be treated clinically with the new Oncentra Optimizer system.


“The Optimizer system provided excellent optimization, dose distribution and segmentation” states Anders Montelius, Chief Physicist at the Akademiska Hospital. “Overall the planning with the software was a positive experience. Optimizer has helped us generate complex treatment plans efficiently, and quickly.” The final dose plans were transferred to the Elekta Precise linac via VISIR™ record and verify system also from Nucletron. The Akademiska Hospital has 4 linear accelerators and provides treatment to over 1,100 new patients per year.


The clinic had been planning to implement IMRT and the MasterPlan treatment planning system assisted in the realization of this goal. “The first case was a head and neck patient and the plan spared potentially damaging radiation to the spinal cord,” says Chief Radiation Oncologist Kristina Nilsson. “We will continue to plan our IMRT patients with Oncentra Optimizer.”


.”.”Oncentra MasterPlan builds on a strong foundation of treatment planning innovation from Nucletron. A unique IMRT module, the product of collaboration with RaySearch Laboratories, from Stockholm, has produced a module called “Optimizer” which enables clinicians to rapidly optimize IMRT plans. In addition, an enhanced evaluation module provides clinicians unprecedented flexibility to review and approve plans. The integration of MasterPlan in the Oncentra information system for oncology, combined with its major advances, transforms traditional planning.


Oncentra MasterPlan is available in all countries worldwide, and is comprehensively supported through Nucletron’s extensive service organization.



About Nucletron B.V.

Nucletron is a global leader in the development, manufacture, sales, service and support of the world’s most innovative products for cancer treatment, with particular expertise in treatment planning systems, brachytherapy, simulation, integrated software solutions for oncology, and comprehensive support and professional education and services. The company has over 20 offices worldwide, including its corporate headquarters in Veenendaal, the Netherlands. For more information on Nucletron, please visit: https://www.nucletron.com/.


Nucletron B.V. is a subsidiary of Delft Instruments. Delft Instruments is the holding company of an international group of companies, which hold a leading position in their respective markets with high quality, high technology products and services. Delft Instruments is active through wholly owned subsidiaries in more than 30 countries worldwide, employs approximately 1,000 people and reported turnover of EUR 261.6 million in 2004. For more information on Delft Instruments, please visit: http://www.delftinstruments.com/.


About RaySearch Laboratories

RaySearch develops and licenses software for radiation therapy of cancer. The company’s products are specially designed to optimize radiation therapy. RaySearch is based in Stockholm, Sweden. For more information on RaySearch, please visit http://www.raysearchlabs.com/

For further information:

Mark Adam General Manager & V.P. Marketing Nucletron B.V. Phone: +31 318 557 149 Fax:     +31 318 557 199 E-mail: mam@nucletron.nl

Tom Chadwick                 Oncentra Marketing Manager               Nucletron B.V.               Phone: + 31 318 557 142               Fax:     + 31 318 557 199               E-mail: tom.chadwick@nl.nucletron.com